American Journal of Cardiology
Volume 105, Issue 1 , Pages 29-35 , 1 January 2010

Efficacy of Ivabradine, a Selective If Inhibitor, in Patients With Chronic Stable Angina Pectoris and Diabetes Mellitus

  • Jeffrey S. Borer, MD

      Affiliations

    • Division of Cardiovascular Medicine, Cardiovascular Translational Research Institute and Howard Gilman Institute for Heart Valve Diseases, State University of New York Downstate Medical Center, Brooklyn, New York
    • Corresponding Author InformationCorresponding author: Tel: (212) 289-7777; fax: (212) 426-4353
    • ,
  • Jean-Claude Tardif, MD

      Affiliations

    • Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada

Received 4 May 2009 ,Revised 7 August 2009 ,Accepted 7 August 2009.

References 

  1. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Rev. 2006;53:399–406
  2. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003;4:83–89
  3. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–155
  4. Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61:127–137
  5. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–823
  6. Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–2536
  7. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393–405
  8. Fox K, Garcia MA, Ardessino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J. 2006;27:1341–1381
  9. Fox K, Ford I, Steg PG, Tendera M, Ferrari M BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816
  10. Tardif JC, Ponikowski P, Kahan T ASSOCIATE study investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540–548
  11. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Fiegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29:1263–1268
  12. Narayan KM, Boyle JP, Geiss LS, Saadine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.A., 2005–2050. Diabetes Care. 2006;29:2114–2116
  13. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–1579
  14. Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD, et al. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2005;28:668–674
  15. Bucchi A, Baruscotti M, Robinson RB, DiFrancesco D. Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current. J Mol Cell Cardiol. 2007;43:39–48
  16. Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B, et al. Resting heart rate in middle age and diabetes development in older age. Diabetes Care. 2008;31:335–339
  17. Ranjadayalan K, Umachandran V, Ambepityia G, Kopelman PG, Mills PG, Timmis AD. Prolonged anginal perceptual threshold in diabetes: effects on exercise capacity and myocardial ischemia. J Am Coll Cardiol. 1990;16:1120–1124
  18. Daly CA, De Stavola B, Lopez Sendon JL, Tavazzi L, Boersma E, Clemens F, et al. Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262–267
  19. Izzedine H, Launay-Vacher V, Deybach C, Bourry E, Barrou B, Deray G. Drug-induced diabetes mellitus. Expert Opin Drug Saf. 2005;4:1097–1109
  20. Blackburn DF, Wilson TW. Antihypertensive medications and blood sugar: theories and implications. Can J Cardiol. 2006;22:229–233
  21. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191–2201
  22. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancatti FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905–912
  23. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906
  24. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–1157
  25. Ostman J, Asplund K, Bystedt T, Dahlof B, Jern S, Kjellstrom T, et al. Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. J Intern Med. 1998;244:95–107
  26. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–2236
  27. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). www.acc.org/clinical/guidelines/stable/stable.pdf2002;Accessed February, 2008
  28. Carasso S, Markiewicz W. Medical treatment of patients with stable angina pectoris referred for coronary angiography: failure of treatment or failure to treat. Clin Cardiol. 2002;25:436–441

 This study was supported by Servier, Neuilly-sur-Seine, France; Drs. Borer and Tardif are paid consultants to Servier.

PII: S0002-9149(09)02207-3

doi: 10.1016/j.amjcard.2009.08.642

American Journal of Cardiology
Volume 105, Issue 1 , Pages 29-35 , 1 January 2010

Article Tools

* Image Usage & Resolution